Modality
ERT
MOA
ALKi
Target
MET
Pathway
PI3K/AKT
TTR AmyloidosisNSCLC
Development Pipeline
Preclinical
~Apr 2023
→ ~Jul 2024
Phase 1
Oct 2024
→ Jul 2031
Phase 1Current
NCT08944735
2,694 pts·TTR Amyloidosis
2024-10→2031-07·Terminated
NCT05981308
955 pts·TTR Amyloidosis
2025-10→2026-05·Not yet recruiting
3,649 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-162mo awayPh2 Data· TTR Amyloidosis
2031-07-135.3y awayPh2 Data· TTR Amyloidosis
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Termina…
P1/2
Not yet…
Catalysts
Ph2 Data
2026-05-16 · 2mo away
TTR Amyloidosis
Ph2 Data
2031-07-13 · 5.3y away
TTR Amyloidosis
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08944735 | Phase 1/2 | TTR Amyloidosis | Terminated | 2694 | UPCR |
| NCT05981308 | Phase 1/2 | TTR Amyloidosis | Not yet recr... | 955 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |